(vianews) - sanofi (san.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| sanofi (san.pa) | €100.46 | 3.51% | 11.77% |
| iba (ibab.br) | €16.52 | 1.18% | 5.01% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. sanofi (san.pa)
3.51% forward dividend yield and 11.77% return on equity
sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the united states, europe, and internationally. it operates through pharmaceuticals, vaccines, and consumer healthcare segments. the company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. in addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis a, typhoid, cholera, yellow fever, and rabies vaccines. the company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. further, it has a collaboration and license agreement with exscientia to develop up to 15 novel small-molecule for oncology and immunology; abl bio, inc. to develop abl301 for parkinson's disease; blackstone life sciences to develop pivotal studies and clinical development program; and seagen inc. to design, develop, and commercialize antibody-drug conjugates for cancer. additionally, the company has a collaboration agreement with igm biosciences, inc. to develop, manufacture, and commercialize igm antibody; skyhawk therapeutics, inc to discover and develop novel small molecules; and amunix pharmaceuticals, inc for t-cell engagers and cytokine therapies. it also enters in a strategic collaboration with scribe therapeutics inc. to develop genome editing technologies; and co-promotion service agreement with provention bio, inc. for the commercialization of teplizumab. the company was formerly known as sanofi-aventis and changed its name to sanofi in may 2011. sanofi was founded in 1973 and is headquartered in paris, france.
earnings per share
as for profitability, sanofi has a trailing twelve months eps of €6.49.
pe ratio
sanofi has a trailing twelve months price to earnings ratio of 15.48. meaning, the purchaser of the share is investing €15.48 for every euro of annual earnings.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.77%.more news about sanofi.
2. iba (ibab.br)
1.18% forward dividend yield and 5.01% return on equity
ion beam applications sa develops, manufactures, and supports medical devices and software solutions for cancer treatments in belgium, the united states, and internationally. the company operates through proton therapy and other accelerators, and dosimetry segments. the proton therapy and other accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. this segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or spect radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. the dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. the company has strategic research and development partnership with sck cen (belgian nuclear research center) to enable the production of actinimum-225 (225ac), a novel radioisotope for the treatment of cancer; and an agreement with university of pennsylvania for advance research in conformalflash. ion beam applications sa was incorporated in 1986 and is headquartered in louvain-la-neuve, belgium.
earnings per share
as for profitability, iba has a trailing twelve months eps of €0.13.
pe ratio
iba has a trailing twelve months price to earnings ratio of 127.08. meaning, the purchaser of the share is investing €127.08 for every euro of annual earnings.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.01%.dividend yield
as claimed by morningstar, inc., the next dividend payment is on jun 29, 2022, the estimated forward annual dividend rate is 0.19 and the estimated forward annual dividend yield is 1.18%.
volume
today's last reported volume for iba is 1316 which is 91.49% below its average volume of 15473.
volatility
iba's last week, last month's, and last quarter's current intraday variation average was 0.25%, 0.23%, and 1.56%.
iba's highest amplitude of average volatility was 0.74% (last week), 1.03% (last month), and 1.56% (last quarter).
more news about iba.